clinical trials

It looks like we'll see oral GLP-1 drugs on the market by 2026, with Eli Lilly reporting impressive results from a large, robust 72-week trial that saw obese patients lose an average of 27.3 lb, or 12.4% of their body weight, with a once-daily pill.

What if you could inject a drug into a "problem area" – like the abdomen – and have it safely and rapidly kill off fat cells? We could be within 12 months of this reality, as the world's first safe, targeted fat-loss jab enters Phase 3 trials.

From St John’s wort to vitamin D, the range of over-the-counter supplements for mental health wellbeing continues to grow. Now, scientists have looked at 64 products reviewed in hundreds of studies to shed light on how useful they are for depression.

A safe and affordable treatment to effectively combat the progress of Parkinson's dementia has emerged – in the form of a commonly available cough syrup that's already being studied for its brain-protecting power in other degenerative diseases.

A clinical trial has shown that Ozempic improves blood glucose levels and weight loss in overweight type 1 diabetics who use an automated insulin delivery system. It’s hoped this will lead to the approval of Ozempic for this patient population.

A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch relief and clear skin for many patients in a clinical trial, without the common side effects associated with other therapies.

Over the weekend, Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing what appears to be a strategic "something for everyone" plan of attack from the pharmaceutical giant.

A novel weight loss drug in the same class as semaglutide has successfully met its targets in the largest clinical trial yet, with nearly 90% of participants losing at least 5% of their body weight. The results strengthen its case for FDA approval.

A promising new treatment to combat "undruggable" cancers has been green-lit for a human trial. It's hoped the novel drug will be able to stunt the growth and enable the effective treatment of cancers driven by the MYC oncogene and its MYC protein.

A final-stage clinical trial comparing a long-acting, once-weekly pill to treat schizophrenia symptoms with the existing daily treatment has found that both produce comparable therapeutic effects. If approved, the drug could simplify patient care.

We could be on the verge of a major cancer breakthrough, with a new nanoparticle-based vaccine reportedly obliterating pancreatic cancer cells in preclinical trials. This success now takes it a step closer to a first-of-its-kind human trial.

Positive results from trials of an immune therapy in dogs with bone cancer have been used to fast-track the development of the drug to treat children with the same cancer. It highlights how leveraging our genetic similarity can advantage both species.